Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

B0935

Sigma-Aldrich

Benazepril hydrochloride

≥98% (HPLC), solid

Synonyma:

(3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid hydrochloride

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C24H28N2O5 · HCl
Číslo CAS:
86541-74-4
Molekulová hmotnost:
460.95
MDL number:
MFCD00895734
UNSPSC Code:
12352200
PubChem Substance ID:
24724409
NACRES:
NA.77

assay

≥98% (HPLC)

form

solid

solubility

H2O: >5 mg/mL

originator

Novartis

SMILES string

Cl[H].CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CCc3ccccc3N(CC(O)=O)C2=O

InChI

1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1

InChI key

VPSRQEHTHIMDQM-FKLPMGAJSA-N

Gene Information

human ... ACE(1636)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Biochem/physiol Actions

Benazepril is a long-acting angiotensin converting enzyme (ACE) inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361fd

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 5

1 of 5

Captopril ≥98% (HPLC), powder

Sigma-Aldrich

C4042

Captopril

Spironolactone European Pharmacopoeia (EP) Reference Standard

S1200000

Spironolactone

Spironolactone United States Pharmacopeia (USP) Reference Standard

USP

1619006

Spironolactone

Lisinopril ≥98% (HPLC)

Sigma-Aldrich

L6292

Lisinopril

Leupeptin microbial, ≥90% (HPLC)

Sigma-Aldrich

L2884

Leupeptin

Yoshihiko Kanno et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 25(6), 939-943 (2002-12-18)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder in humans. Hypertension is one of the major complications, and its control might affect the renal survival and disease mortality. Suitable antihypertensive agents have been discussed based
Daphne P Bicket
American family physician, 66(3), 461-468 (2002-08-17)
When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were indicated only for treatment of refractory hypertension. Since then, they have been shown to reduce morbidity or mortality in congestive heart failure, myocardial infarction, diabetes mellitus, chronic renal insufficiency, and
A Salvetti et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 12(8), S91-S94 (1994-11-01)
SHORT- VERSUS LONG-ACTING ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS: Although ACE inhibitors are widely used in the treatment of hypertension, there are few data on trough:peak ratios and the data are contradictory. Part of the explanation for this lies in differences
Bjoern B Burckhardt et al.
Journal of pharmaceutical and biomedical analysis, 96, 118-126 (2014-04-18)
Although serum and plasma are the biological fluids of choice for pharmacokinetic determination of drugs in adults, it is desirable to elucidate noninvasive methods which can be used for investigations in vulnerable groups such as children. If the drug properties
Nadine Bongaerts et al.
Nature communications, 13(1), 3905-3905 (2022-07-08)
Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the pathogen's slow growth and biocontainment requirements. Here we present a synthetic biology framework for assaying Mtb drug targets in engineered E. coli. We construct Target Essential Surrogate E. coli
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.